超分辨超声成像监测血管阻断剂在乳腺癌动物模型中的治疗疗效
研究在28只雌性裸鼠乳腺脂肪垫植入人乳腺癌细胞,用超分辨超声(SRUS)在血管阻断剂CA4P或生理盐水前后4及24小时评估肿瘤血流参数。结果显示SRUS衍生的峰值增强和灌注速率在治疗组4及24小时显著下降,而对照组无变化,提示SRUS可用于早期评估血管阻断剂疗效。
要点
- SRUS可在VDA治疗后4小时检出肿瘤灌注参数下降,早于传统形态学变化。
- SRUS微血管图谱显示治疗组血管密度在4及24小时低于对照组。
- SRUS为评估肿瘤对血管阻断剂反应的新的影像学方法。
核心结论
- SRUS成像是一种评估肿瘤对血管阻断剂治疗反应的新方法。
研究设计与样本
- 动物实验:28只雌性裸鼠(Charles River Laboratories)乳腺脂肪垫植入人乳腺癌细胞(MDA-MB-231,ATCC),使用Vevo 3100超声仪(FUJIFILM VisualSonics Inc)配MX250线阵探头,经尾静脉团注微泡造影剂(Definity,Lantheus Medical Imaging),基线成像后经导管注射CA4P(Sigma Aldrich)或对照生理盐水,4或24小时后重复同一肿瘤横截面成像;用校准传感器直接测量瘤内压力;原始数据离线用MATLAB(MathWorks Inc)重建SRUS图像;终点用番茄凝集素标记通畅血管量化瘤内微血管密度(MVD)。
关键影像表现/征象
- SRUS图像在对照组与治疗组肿瘤之间显示出明显差异。
- SRUS衍生的峰值增强(PE)和灌注速率(WIR)在VDA治疗组4小时(分别为P = .03和P = .05)及24小时(分别为P = .02和P = .01)显著下降。
- 对照组肿瘤的PE和WIR无显著变化(P > .22)。
- SRUS微血管图谱在基线无差异(P = .81),但治疗组血管密度在4及24小时均低于对照组(P < .04)。
- 对照肿瘤中瘤内压力与PE和WIR参数呈负相关(R2 > .09,P < .03)。
临床应用与阅片要点
- SRUS可显示VDA治疗后肿瘤灌注参数(PE、WIR)和微血管密度的早期下降,可用于监测治疗反应。
- 基线时各组参数无差异(0小时,P > .09),提示SRUS变化需与基线对比解读。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Evaluate the use of super-resolution ultrasound (SRUS) imaging for the early detection of tumor response to treatment using a vascular-disrupting agent (VDA).
METHODS: A population of 28 female nude athymic mice (Charles River Laboratories) were implanted with human breast cancer cells (MDA-MB-231, ATCC) in the mammary fat pad and allowed to grow. Ultrasound imaging was performed using a Vevo 3100 scanner (FUJIFILM VisualSonics Inc) equipped with the MX250 linear array transducer immediately before and after receiving bolus injections of a microbubble (MB) contrast agent (Definity, Lantheus Medical Imaging) via the tail vein. Following baseline ultrasound imaging, VDA drug (combretastatin A4 phosphate, CA4P, Sigma Aldrich) or control saline was injected via the placed catheter. After 4 or 24 hours, repeat ultrasound imaging along the same tumor cross-section occurred. Direct intratumoral pressure measurements were obtained using a calibrated sensor. All raw ultrasound data were saved for offline processing and SRUS image reconstruction using custom MATLAB software (MathWorks Inc). From a region encompassing the tumor space and the entire postprocessed ultrasound image sequence, time MB count (TMC) curves were generated in addition to traditional SRUS maps reflecting MB enumeration at each pixel location. Peak enhancement (PE) and wash-in rate (WIR) were extracted from these TMC curves. At termination, intratumoral microvessel density (MVD) was quantified using tomato lectin labeling of patent blood vessels.
RESULTS: SRUS images exhibited a clear difference between control and treated tumors. While there was no difference in any group parameters at baseline (0 hour, P > .09), both SRUS-derived PE and WIR measurements in tumors treated with VDA exhibited significant decreases by 4 (P = .03 and P = .05, respectively) and 24 hours (P = .02 and P = .01, respectively), but not in control group tumors (P > .22). Similarly, SRUS derived microvascular maps were not different at baseline (P = .81), but measures of vessel density were lower in treated tumors at both 4 and 24 hours (P < .04). An inverse relationship between intratumoral pressure and both PE and WIR parameters were found in control tumors (R2 > .09, P < .03).
CONCLUSION: SRUS imaging is a new modality for assessing tumor response to treatment using a VDA.
引用
- Hoyt K. Super-Resolution Ultrasound Imaging for Monitoring the Therapeutic Efficacy of a Vascular Disrupting Agent in an Animal Model of Breast Cancer. J Ultrasound Med. 2024. PMID: 38411352. doi:10.1002/jum.16438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。